Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,232 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,676 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01415882 | Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib | completed | Phase 2 | 165 | Mayo ClinicOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03568994 | Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)(ATACC AML) | completed | Early Phase 1 | 26 | Baylor College of MedicineOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03901963 | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant(AURIGA) | completed | Phase 3 | 200 | Janssen Research & Development, LLCINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT04252508 | Impact of a Double-reading Animated Film (Child, Parents) in Preoperative on the Anxiety of Children Upon Arrival at the Operating Room(VERAPOP) | completed | N/A | 80 | University Hospital, BordeauxOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03651128 | Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)(KarMMa-3) | completed | Phase 3 | 386 | CelgeneINDUSTRY | 13 | Jun 22, 2026 | clinicaltrials |
| NCT04260698 | Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies | completed | Phase 3 | 36 | Gamida Cell ltdINDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04471961 | Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia(ALADIN) | completed | N/A | 100 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT00081874 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT04045561 | Development of a Standardized Reference Guide for Tuning Adherence to Dispense During a Initial Pharmaceutical Consulting (CP ) to the Patient With Multiple Myeloma Oral Chemotherapy Primocure | completed | — | 10 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05654194 | Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML | completed | Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT01242930 | Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma | completed | Phase 2 | 13 | Geron CorporationINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05024994 | A Study of E7820 in People With Bone Marrow (Myeloid) Cancers | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05422521 | Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma(CART-Omic) | completed | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01644799 | Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma | completed | Phase 1 | 8 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT01838434 | Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 1 | 106 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03602612 | T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04965649 | Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.(TIPHI) | completed | — | 30 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05818644 | Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children(HEPATIC) | completed | — | 583 | University Medical Center GroningenOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03447808 | Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | completed | Phase 1 | 15 | Jennifer WoyachOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03839459 | Denosumab for Smoldering Multiple Myeloma | completed | Phase 2 | 20 | University of RochesterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04737265 | Pilot Study of an NTproBNP Guided Strategy of Cardioprotection(NTproBNP-Guide) | completed | Phase 1 / Phase 2 | 108 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT02232516 | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03570892 | Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma(BELINDA) | completed | Phase 3 | 330 | Novartis PharmaceuticalsINDUSTRY | 18 | Jun 12, 2026 | clinicaltrials |
| NCT04113226 | Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma(Relyage) | completed | Phase 2 | 1 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07644351 | A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients(ASCERTAIN) | completed | — | 37 | Novartis PharmaceuticalsINDUSTRY | 12 | Jun 12, 2026 | clinicaltrials |
| NCT02332850 | Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 83 | Thomas Martin, MDOTHER | 2 | Jun 11, 2026 | clinicaltrials |
| NCT05978739 | Evaluating Different Doses of Orelabrutinib in MCL | completed | Phase 2 | 40 | InnoCare Pharma Inc.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02242097 | Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma | completed | Phase 2 | 37 | Northwestern UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03505554 | A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma(CRU3) | completed | Phase 2 | 9 | University of Milano BicoccaOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04833114 | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)(Pola-R-ICE) | completed | Phase 3 | 306 | GWT-TUD GmbHOTHER | 4 | Jun 10, 2026 | clinicaltrials |
| NCT05620238 | Home Treatment With Carfilzomib in Patients With Multiple Myeloma | completed | — | 9 | Thomas LundOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06026644 | Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life(LNH012) | completed | — | 170 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT02997761 | Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia | completed | Phase 2 | 19 | University of California, DavisOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05177211 | Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | completed | Phase 2 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06525116 | MRD Detection by NGS in Pediatric T-ALL | completed | — | 148 | The Children's Hospital of Zhejiang University School of MedicineOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03244306 | A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma(PLAT-04) | completed | Phase 1 | 4 | Seattle Children's HospitalOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03301220 | A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma | completed | Phase 3 | 390 | Janssen Research & Development, LLCINDUSTRY | 24 | Jun 8, 2026 | clinicaltrials |
| NCT03494179 | A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) | completed | Phase 1 / Phase 2 | 106 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT00107198 | Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease | completed | Phase 2 | 188 | Children's Oncology GroupNETWORK | 6 | Jun 5, 2026 | clinicaltrials |
| NCT01702831 | Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance(BuMelMCRN001) | completed | Phase 2 | 78 | University Health Network, TorontoOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04188405 | Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04696809 | A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04848974 | Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05715047 | Intervention for Fatigue in HCT Recipients | completed | N/A | 66 | Massachusetts General HospitalOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT00185757 | Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation | completed | Phase 1 | 21 | Stanford UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT01868451 | Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma | completed | N/A | 118 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02158858 | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies | completed | Phase 1 / Phase 2 | 336 | Constellation PharmaceuticalsINDUSTRY | 9 | Jun 4, 2026 | clinicaltrials |
| NCT02286726 | CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 23, 2026source: clinicaltrials